The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...